



This is a repository copy of *A generalizable data-driven model of atrophy heterogeneity and progression in a memory clinic setting*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/221741/>

Version: Published Version

Proceedings Paper:

Baumeister, H., Vogel, J.W., Insel, P.S. et al. (55 more authors) (2024) A generalizable data-driven model of atrophy heterogeneity and progression in a memory clinic setting. In: *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. Alzheimer's Association International Conference 2024 (AAIC 2024), 28 Jul - 01 Aug 2024, Philadelphia, USA. Wiley

<https://doi.org/10.1002/alz.092184>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

A generalizable data-driven model of atrophy heterogeneity and progression in a memory clinic setting

Hannah Baumeister¹ | Jacob W. Vogel² | Philip S. Insel³ | Luca Kleineidam^{4,5} | Steffen Wolfsgruber^{4,5} | Melina Stark⁴ | Helena M. Gellersen¹ | Renat Yakupov^{1,6} | Matthias Schmid^{5,7} | Falk Lüsebrink¹ | Frederic Brosseron⁵ | Gabriel Ziegler⁶ | Silka Dawn Freiesleben^{8,9} | Lukas Preis¹⁰ | Luisa Sophie Schneider⁸ | Eike Jakob Spruth^{9,11} | Slawek Altenstein^{9,11} | Andrea Lohse¹¹ | Klaus Fliessbach^{4,5} | Ina R Vogt⁵ | Claudia Bartels¹² | Björn H. Schott^{12,13} | Ayda Rostamzadeh¹⁴ | Wenzel Glanz¹ | Enise I Incesoy^{6,9,15} | Michaela Butryn¹ | Daniel Janowitz¹⁶ | Boris-Stephan Rauchmann^{17,18,19} | Ingo Kilimann^{20,21} | Doreen Goerss^{20,21} | Matthias H. J. Munk^{22,23} | Stefan Hetzer⁸ | Peter Dechent²⁴ | Michael Ewers^{16,25} | Klaus Scheffler²⁶ | Anika Wuestefeld² | Olof Strandberg² | Danielle van Westen^{27,28} | Niklas Mattsson-Carlgren^{2,29,30} | Shorena Janelidze² | Erik Stomrud^{2,31} | Sebastian Palmqvist^{2,31} | Annika Spottke^{5,32} | Christoph Laske^{22,33,34} | Stefan Teipel^{20,21} | Robert Perneczky^{18,25,35,36} | Katharina Buerger^{16,25} | Anja Schneider^{4,5} | Josef Priller^{8,9,37,38} | Oliver Peters^{8,9} | Alfredo Ramirez^{4,5,39,40,41} | Jens Wiltfang^{12,13,42} | Michael T. Heneka⁴³ | Michael Wagner^{4,5} | Emrah Düzel^{1,6,44} | Frank Jessen^{5,14,41} | Oskar Hansson^{2,31} | David Berron^{1,2,44}

¹German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany

²Clinical Memory Research Unit, Lund University, Lund, Sweden

³Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA

⁴Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn Medical Center, Bonn, Germany

⁵German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

⁶Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany

⁷Institute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany

⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

⁹German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

¹⁰Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin – Institute of Psychiatry and Psychotherapy, Berlin, Germany

¹¹Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany

¹²University Medical Center Goettingen (UMG), Goettingen, Germany

¹³German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Alzheimer's Association. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

- ¹⁴Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- ¹⁵Department of Psychiatry and Psychotherapy, Otto-von-Guericke University, Magdeburg, Germany
- ¹⁶Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany
- ¹⁷Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom
- ¹⁸Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
- ¹⁹Department of Neuroradiology, LMU University Hospital, Munich, Germany, Munich, Germany
- ²⁰German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
- ²¹Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
- ²²Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany
- ²³German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany
- ²⁴MR-Research in Neurosciences, Georg-August-University Goettingen, Germany, Goettingen, Germany
- ²⁵German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- ²⁶University of Tübingen, Tübingen, Germany
- ²⁷Imaging and Function, Skåne University Hospital, Lund, Sweden
- ²⁸Diagnostic Radiology, Department of Clinical Sciences, Lund University, Lund, Sweden
- ²⁹Department of Neurology, Skåne University Hospital, Lund, Sweden
- ³⁰Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
- ³¹Memory Clinic, Skåne University Hospital, Malmö, Sweden
- ³²Department of Neurology, University of Bonn, Bonn, Germany
- ³³Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany
- ³⁴German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- ³⁵LMU University Hospital, Munich, Germany
- ³⁶Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- ³⁷Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany
- ³⁸University of Edinburgh and UK DRI, Edinburgh, United Kingdom
- ³⁹Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- ⁴⁰Department of Psychiatry and Glenn, Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
- ⁴¹Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- ⁴²Medical Science Department, iBiMED, University of Aveiro, Aveiro, Portugal
- ⁴³Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Luxembourg, Luxembourg
- ⁴⁴Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany

Correspondence

Hannah Baumeister, German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Email: Hannah.Baumeister@dzne.de

Abstract


Background: Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer's disease (AD) patients, are prevalent and clinically meaningful in this group of older adults.

Method: To uncover atrophy subtypes, we applied the Subtype and Stage Inference (SuStaln) algorithm to structural MRI data from 813 participants (mean \pm SD age = 70.67 \pm 6.07 years, 52% females) from the DELCODE cohort. Participants were cognitively unimpaired (CU; n = 285) or patients with subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer's type (n = 68). Atrophy subtypes were compared in baseline demographics,

fluid AD biomarkers, and domain-specific cognitive performance. PACC-5 trajectories over up to 240 weeks were examined. Clinical trajectories (PACC-5 scores and MCI conversion rates) in only CU and SCD participants were analysed. SuStaln modelling was repeated in participants from the Swedish BioFINDER-2 study for replication and generalizability testing.




Result: Limbic-predominant and hippocampal-sparing atrophy subtypes were identified (Figure 1). Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. This subtype was related to older age, more pathological AD biomarkers, APOE $\epsilon 4$ carriership, and an amnesic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe and spared the medial temporal lobe until advanced stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy (Figure 2) and increased the risk of MCI conversion. In BioFINDER-2, analogous atrophy subtypes and cognitive correlates were identified. Group- and subject-level model generalizability were excellent, indicating reliable performance in novel data (Figure 3).

Conclusion: The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.



Baseline atrophy subtype

--- Atrophy-negative — Limbic-predominant Hippocampal-sparing



Baseline SuStain stage

..... 1-2 — 3-10

